MCID: PLG002
MIFTS: 56

Plague

Categories: Immune diseases, Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Plague

MalaCards integrated aliases for Plague:

Name: Plague 12 76 59 43 3 15 73
Yersiniosis 59 3
Yersinia Infections 73

Characteristics:

Orphanet epidemiological data:

59
plague
Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:3482
ICD10 33 A20 A20.9
ICD9CM 35 020 020.9
MeSH 44 D010930
NCIt 50 C85015
SNOMED-CT 68 58750007
Orphanet 59 ORPHA707
MESH via Orphanet 45 D010930 D015009
UMLS via Orphanet 74 C0032064 C0043407
ICD10 via Orphanet 34 A20.0 A20.1 A20.2 more

Summaries for Plague

MedlinePlus : 43 Plague is an infection caused by the bacterium Yersinia pestis. The bacteria are found mainly in rats and in the fleas that feed on them. People and other animals can get plague from rat or flea bites. In the past, plague destroyed entire civilizations. Today plague is uncommon, due to better living conditions and antibiotics. There are three forms of plague: Bubonic plague causes the tonsils, adenoids, spleen, and thymus to become inflamed. Symptoms include fever, aches, chills, and tender lymph glands. In septicemic plague, bacteria multiply in the blood. It causes fever, chills, shock, and bleeding under the skin or other organs. Pneumonic plague is the most serious form. Bacteria enter the lungs and cause pneumonia. People with the infection can spread this form to others. This type could be a bioterror agent. Lab tests can diagnose plague. Treatment is a strong antibiotic. There is no vaccine. NIH: National Institute of Allergy and Infectious Diseases

MalaCards based summary : Plague, also known as yersiniosis, is related to bubonic plague and septicemic plague, and has symptoms including fever and pruritus. An important gene associated with Plague is CCR5 (C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)), and among its related pathways/superpathways are Human cytomegalovirus infection and NF-kappaB Signaling. The drugs Hydroxymethylglutaryl-CoA Reductase Inhibitors and Hypolipidemic Agents have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and testes, and related phenotypes are cellular and cardiovascular system

Disease Ontology : 12 A primary bacterial infectious disease that results in infection, located in lymph node, located in vasculature or located in lungs, has material basis in Yersinia pestis, which is transmitted by oriental rat flea (Xenopsylla cheopis) infected by feeding on rodents and other mammals, transmitted by air, transmitted by direct contact or transmitted by ingestion of contaminated undercooked food.

CDC : 3 Plague

Wikipedia : 76 Plague is an infectious disease caused by the bacterium Yersinia pestis. Symptoms include fever,... more...

Related Diseases for Plague

Diseases related to Plague via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Related Disease Score Top Affiliating Genes
1 bubonic plague 34.3 CCR5 PLG
2 septicemic plague 34.1 MYD88 PLG
3 pneumonic plague 34.0 PLG SULT1A2
4 tularemia 11.4
5 anthrax disease 11.4
6 sulfamethoxazole allergy 10.2 CD83 CD86
7 influenza 10.2
8 smallpox 10.2
9 myositis fibrosa 10.1 CD86 MYD88
10 pulmonary vein stenosis 10.1 PECAM1 TYMP
11 arthritis 10.1
12 listeriosis 10.1
13 reactive arthritis 10.1
14 typhoid fever 10.1
15 cholera 10.1
16 exanthema subitum 10.1 CD83 CD86
17 chronic myocardial ischemia 10.1 PLG TYMP
18 blastic plasmacytoid dendritic cell 10.0 MYD88 PECAM1
19 hemangioendothelioma 10.0 PECAM1 PLG
20 variola major 10.0
21 ecthyma 10.0
22 pneumonia 10.0
23 campylobacteriosis 10.0
24 paracoccidioidomycosis 10.0 CD86 MYD88
25 endophthalmitis 10.0 PLG SELE
26 legionnaire disease 9.9
27 malaria 9.9
28 rocky mountain spotted fever 9.9
29 endemic typhus 9.9
30 legionnaires' disease 9.9
31 legionellosis 9.9
32 bartonellosis 9.9
33 spotted fever 9.9
34 lyme disease 9.9
35 dysentery 9.9
36 relapsing fever 9.9
37 schistosomiasis 9.9
38 leptospirosis 9.9
39 human immunodeficiency virus infectious disease 9.9
40 measles 9.9
41 kawasaki disease 9.9
42 myd88 deficiency 9.9
43 beta-thalassemia 9.9
44 glomerulonephritis 9.9
45 hemophagocytic lymphohistiocytosis 9.9
46 thalassemia 9.9
47 ileitis 9.9
48 salmonellosis 9.9
49 chlamydia 9.9
50 hemosiderosis 9.9

Graphical network of the top 20 diseases related to Plague:



Diseases related to Plague

Symptoms & Phenotypes for Plague

UMLS symptoms related to Plague:


fever, pruritus

MGI Mouse Phenotypes related to Plague:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 CCR5 CD86 CDC25C DDX58 INVS MGAT1
2 cardiovascular system MP:0005385 10.09 CCR5 CD83 INVS MGAT1 MYD88 PECAM1
3 digestive/alimentary MP:0005381 9.97 CCR5 CDC25C DDX58 INVS MYD88 PECAM1
4 hematopoietic system MP:0005397 9.96 CCR5 CD83 CD86 DDX58 INVS MGAT1
5 endocrine/exocrine gland MP:0005379 9.92 CD83 CD86 CDC25C INVS MGAT1 MYD88
6 homeostasis/metabolism MP:0005376 9.9 CCR5 CD86 DDX58 INVS MGAT1 MYD88
7 immune system MP:0005387 9.65 CCR5 CD83 CD86 DDX58 INVS MYD88
8 liver/biliary system MP:0005370 9.1 CCR5 DDX58 INVS PECAM1 PLG SELE

Drugs & Therapeutics for Plague

Drugs for Plague (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 192)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2
2 Hypolipidemic Agents Phase 4
3 Anticholesteremic Agents Phase 4
4 Calcium, Dietary Phase 4,Phase 3
5 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1
6 Rosuvastatin Calcium Phase 4 147098-20-2
7 Lipid Regulating Agents Phase 4
8 Aluminum phosphate Phase 4,Not Applicable
9 Antacids Phase 4,Phase 1
10 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
11 Anti-Ulcer Agents Phase 4,Phase 1
12 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1
13 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
14 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
16
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
17
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
18 Vedolizumab Approved Phase 3 943609-66-3
19
Etanercept Approved, Investigational Phase 3 185243-69-0
20
Morphine Approved, Investigational Phase 3 57-27-2 5288826
21
Interferon beta-1a Approved, Investigational Phase 2, Phase 3 145258-61-3 6438354
22
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
23
Thrombin Approved, Investigational Phase 3
24
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
25
Ofloxacin Approved Phase 3 82419-36-1 4583
26
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
27
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
28
leucovorin Approved Phase 3,Phase 2,Early Phase 1 58-05-9 6006 143
29
Crizotinib Approved Phase 3,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
30
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
31
Tofacitinib Approved, Investigational Phase 3,Phase 2 477600-75-2
32
Racepinephrine Approved Phase 2, Phase 3,Not Applicable 329-65-7 838
33
Epinephrine Approved, Vet_approved Phase 2, Phase 3,Not Applicable 51-43-4 5816
34
Methotrexate Approved Phase 3,Phase 2,Early Phase 1 59-05-2, 1959-05-2 126941
35
Etoposide Approved Phase 3,Phase 1,Phase 2,Early Phase 1 33419-42-0 36462
36
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
37
Cytarabine Approved, Investigational Phase 3,Early Phase 1 147-94-4 6253
38 tannic acid Approved Phase 3,Not Applicable
39
Benzocaine Approved, Investigational Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
40
Pimavanserin Approved, Investigational Phase 3,Phase 2 706779-91-1 16058810
41
Adalimumab Approved Phase 3 331731-18-1 16219006
42
mometasone furoate Approved, Vet_approved Phase 3 83919-23-7
43
Pregabalin Approved, Illicit, Investigational Phase 3 148553-50-8 5486971
44
Dimethyl fumarate Approved, Investigational Phase 3 624-49-7 637568 5271565
45
Warfarin Approved Phase 3 81-81-2 6691 54678486
46
Fondaparinux Approved, Investigational Phase 3 104993-28-4
47
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
48 Edoxaban Approved Phase 3 480449-70-5
49
Enoxaparin Approved Phase 3 9005-49-6 772
50
Phytonadione Approved, Investigational Phase 3 84-80-0 4812 5284607

Interventional clinical trials:

(show top 50) (show all 127)
# Name Status NCT ID Phase Drugs
1 Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging Unknown status NCT02041117 Phase 4 Rosuvastatin
2 Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons Completed NCT01404182 Phase 4
3 Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years Completed NCT01424228 Phase 4 placebo;prucalopride
4 EASY: Extended Access to Sollpura Over Years Completed NCT02823964 Phase 4 Liprotamase
5 Treatment and Diagnosis of Plague Completed NCT00128466 Phase 2, Phase 3 gentamicin;streptomycin
6 Mouse Allergen and Asthma Intervention Trial Completed NCT01251224 Phase 3
7 Study to Assess if ABP798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Rituximab Completed NCT02792699 Phase 3 ABP 798;Rituximab
8 A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension Completed NCT00644605 Phase 3 sildenafil;sildenafil;placebo;sildenafil
9 SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis Completed NCT02279498 Phase 3 Liprotamase;porcine (pig) PERT
10 Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy Completed NCT00676507 Phase 3
11 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis Completed NCT02611830 Phase 3 Vedolizumab IV 300 mg;Placebo IV;Vedolizumab SC 108 mg;Placebo SC
12 A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations Completed NCT02413580 Phase 3
13 Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects Completed NCT02378506 Phase 3
14 Phase 3 Study of RPC1063 in Relapsing MS Completed NCT02294058 Phase 3 RPC1063;Beta interferon
15 Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study) Completed NCT02047734 Phase 2, Phase 3 RPC1063 0.5 mg;RPC1063 1 mg;RPC1063 placebo;Interferon β-1a;IFN β-1a placebo
16 Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) Completed NCT02239120 Phase 3 optional ASA as comedication;placebo to ASA;placebo to optional ASA as comedication;placebo to dabigatran etexilate;ASA 100 mg;dabigatran etexilate
17 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) Completed NCT01307423 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo
18 PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Completed NCT01212757 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo + 20 mg Apremilast;Placebo + 30 mg Apremilast
19 Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™ Completed NCT00445185 Phase 3
20 A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B. Completed NCT00291941 Phase 3
21 LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy Completed NCT01523587 Phase 3 afatinib;erlotinib
22 Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections Completed NCT01978938 Phase 3 Eravacycline;Levofloxacin
23 An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Completed NCT00932893 Phase 3 PF-02341066;Pemetrexed;Docetaxel
24 A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065 Recruiting NCT03398135 Phase 3 risankizumab;placebo for risankizumab
25 Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia Recruiting NCT03121586 Phase 3 Pimavanserin
26 Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1) Recruiting NCT02970292 Phase 3 Pimavanserin;Placebo
27 A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy Recruiting NCT03398148 Phase 2, Phase 3 risankizumab IV;placebo for risankizumab;risankizumab SC
28 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug Recruiting NCT03104400 Phase 3 Adalimumab;ABT-494;Placebo for ABT-494;Placebo for Adalimumab
29 Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma Recruiting NCT02892344 Phase 3 QMF149 150/80 μg;MF 200 μg
30 A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Recruiting NCT03114657 Phase 3 Crenezumab;Placebo
31 Vedolizumab Subcutaneous Long-Term Open-Label Extension Study Recruiting NCT02620046 Phase 3 Vedolizumab SC
32 Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 Recruiting NCT02403323 Phase 3 etrolizumab
33 A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD) Recruiting NCT02394028 Phase 3 Etrolizumab;Placebo
34 A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02165215 Phase 3 Etrolizumab;Placebo
35 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies Recruiting NCT02118584 Phase 3 Etrolizumab
36 A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02100696 Phase 3 Etrozulimab;Placebo
37 A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures. Recruiting NCT01747915 Phase 3 Pregabalin Dose Level 1;Pregabalin Dose Level 2;Placebo
38 A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy Recruiting NCT03345849 Phase 3 Upadacitinib;Placebo for Upadacitinib
39 Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) Recruiting NCT02907177 Phase 3 Ponesimod
40 Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS) Recruiting NCT03502616 Phase 3 Tofacitinib
41 A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures Recruiting NCT01463306 Phase 3 Pregabalin
42 Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) Recruiting NCT02798471 Phase 3 Edoxaban;Standard of Care
43 Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns Active, not recruiting NCT02700828 Phase 2, Phase 3 Hydrocortisone;Placebo
44 A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate Active, not recruiting NCT02706873 Phase 3 ABT-494 matching placebo;Methotrexate;Methotrexate matching placebo;ABT-494
45 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate Active, not recruiting NCT02629159 Phase 3 Placebo for Adalimumab;ABT-494;Adalimumab;Placebo for ABT-494
46 Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC Active, not recruiting NCT03260894 Phase 3 Pembrolizumab;Epacadostat;Sunitinib;Pazopanib
47 A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) Active, not recruiting NCT03066778 Phase 3 Normal saline solution;Carboplatin;Cisplatin;Etoposide
48 Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) Active, not recruiting NCT03061812 Phase 3 Rovalpituzumab tesirine;Topotecan
49 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Active, not recruiting NCT02555683 Phase 3 QAW039;QAW039;Placebo
50 (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive Active, not recruiting NCT02039726 Phase 3 Quizartinib;Salvage Chemotherapy

Search NIH Clinical Center for Plague

Genetic Tests for Plague

Anatomical Context for Plague

MalaCards organs/tissues related to Plague:

41
Lung, Lymph Node, Testes, Skin, Spleen, Tonsil, Thymus

The Foundational Model of Anatomy Ontology organs/tissues related to Plague:

19
Lymph Node, Vasculature Or

Publications for Plague

Articles related to Plague:

(show top 50) (show all 1421)
# Title Authors Year
1
Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine. ( 30467064 )
2019
2
Escherichia coli expressed flagellin C (FliC) of Salmonella Typhi improved the protective efficacy of YopE against plague infection. ( 30497835 )
2019
3
SCIENTISTS and SCIENCE ADVOCATES: Dr. Younes Karimi (1929-2008), the Prominent Iranian Physician in the Field of Plague and Other Infectious Diseases ( 29380589 )
2019
4
The Deer Mouse (Peromyscus maniculatus) as an Enzootic Reservoir of Plague in California. ( 29700709 )
2018
5
Reemergence of human plague in Yunnan, China in 2016. ( 29897940 )
2018
6
Plague disease model with weather seasonality. ( 29800562 )
2018
7
Of mice and men: Traces of life in the death registries of the 1630 plague in Milano. ( 29305937 )
2018
8
The 2017 plague outbreak in Madagascar: Data descriptions and epidemic modelling. ( 29866421 )
2018
9
Plague: Bridging gaps towards better disease control. ( 29773334 )
2018
10
Fumigating the Hygienic Model City: Bubonic Plague and the Sulfurozador in Early-Twentieth-Century Buenos Aires. ( 29886876 )
2018
11
Human case of bubonic plague resulting from the bite of a wild Gunnison's prairie dog during translocation from a plague-endemic area. ( 29110441 )
2018
12
Mixed pneumonic plague and nosocomial MDR-bacterial infection of lung: a rare case report. ( 29843675 )
2018
13
Phylogeny and Classification of <i>Yersinia pestis</i> Through the Lens of Strains From the Plague Foci of Commonwealth of Independent States. ( 29887859 )
2018
14
Six Whole-Genome Assemblies of Yersinia pestis subsp. microtus bv. ulegeica (Phylogroup 0.PE5) Strains Isolated from Mongolian Natural Plague Foci. ( 29930050 )
2018
15
Nine Whole-Genome Assemblies of<i>Yersinia pestis</i>subsp.<i>microtus</i>bv. Altaica Strains Isolated from the Altai Mountain Natural Plague Focus (No. 36) in Russia. ( 29348336 )
2018
16
An Evaluation of Removal Trapping to Control Rodents Inside Homes in a Plague-Endemic Region of Rural Northwestern Uganda. ( 29768127 )
2018
17
A historical evaluation of Chinese tongue diagnosis in the treatment of septicemic plague in the pre-antibiotic era, and as a new direction for revolutionary clinical research applications. ( 29691189 )
2018
18
The Resistance to Plague Infection among<i>Meriones persicus</i>from Endemic and Non-endemic Regions in Iran: The Role of Gut Microbiota. ( 29318122 )
2018
19
Simultaneous immunodetection of anthrax, plague and tularemia from blood cultures utilizing multiplexed suspension arrays. ( 29386263 )
2018
20
Human ectoparasites and the spread of plague in Europe during the Second Pandemic. ( 29339508 )
2018
21
Detecting plague-host abundance from space: Using a spectral vegetation index to identify occupancy of great gerbil burrows. ( 29399006 )
2018
22
Impact of Sylvatic Plague Vaccine on Non-target Small Rodents in Grassland Ecosystems. ( 29744628 )
2018
23
New genotyping method for the causative agent of crayfish plague (Aphanomyces astaci) based on whole genome data. ( 29953875 )
2018
24
Identifying the social and environmental determinants of plague endemicity in Peru: insights from a case study in Ascope, La Libertad. ( 29409470 )
2018
25
Ecologic Features of Plague Outbreak Areas, Democratic Republic of the Congo, 2004-2014. ( 29350136 )
2018
26
Depletion of Glucose Activates Catabolite Repression during Pneumonic Plague. ( 29555700 )
2018
27
One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults: An extended open-label study. ( 29927704 )
2018
28
Madagascar can build stronger health systems to fight plague and prevent the next epidemic. ( 29300731 )
2018
29
Hidden sites in the distribution of the crayfish plague pathogen Aphanomyces astaci in Eastern Europe: Relicts of genetic groups from older outbreaks? ( 29787742 )
2018
30
Plague in Madagascar - A Tragic Opportunity for Improving Public Health. ( 29261403 )
2018
31
Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. ( 29725025 )
2018
32
Pneumonic plague epidemic in Northeast China in 1910-1911: Dr. Wu Lien-Teh's epidemic preventive system for plague control. ( 29372498 )
2018
33
Investigation of Pneumonic Plague, Madagascar. ( 29260670 )
2018
34
Humoral and cellular immune responses to Yersinia pestis Pla antigen in humans immunized with live plague vaccine. ( 29889829 )
2018
35
Molecular epidemiological investigations of plague in Eastern Province of Zambia. ( 29433443 )
2018
36
Inhalational Gentamicin Treatment Is Effective Against Pneumonic Plague in a Mouse Model. ( 29740404 )
2018
37
Analysis of 3800-year-old Yersinia pestis genomes suggests Bronze Age origin for bubonic plague. ( 29884871 )
2018
38
Targeting of the Yersinia pestis F1 capsular antigen by innate-like B1b cells mediates a rapid protective response against bubonic plague. ( 30374415 )
2018
39
Yersiniosis or Leśniowski-Crohn's disease. ( 29513254 )
2018
40
The Plague of Plagiarism: Prevention and Cure!!! ( 30416266 )
2018
41
Plague Masks: The Visual Emergence of Anti-Epidemic Personal Protection Equipment. ( 30427733 )
2018
42
Estimation of Pneumonic Plague Transmission in Madagascar, August-November 2017. ( 30450266 )
2018
43
Integrative approach using Yersinia pestis genomes to revisit the historical landscape of plague during the Medieval Period. ( 30478041 )
2018
44
A critical review of anthropological studies on skeletons from European plague pits of different epochs. ( 30518882 )
2018
45
Exposure to Yersinia pestis increases resistance to plague in black rats and modulates transmission in Madagascar. ( 30551741 )
2018
46
Duck stimulator of interferon genes plays an important role in host anti-duck plague virus infection through an IFN-dependent signalling pathway. ( 28969942 )
2018
47
Plague: Recognition, Treatment, and Prevention. ( 29070654 )
2018
48
Stress, sex, and plague: Patterns of developmental stress and survival in pre- and post-Black Death London. ( 29071763 )
2018
49
A safety and immunogenicity study of a novel subunit plague vaccine in cynomolgus macaques. ( 29134676 )
2018
50
Phenotypic and Molecular Genetic Characteristics of Yersinia pestis at an Emerging Natural Plague Focus, Junggar Basin, China. ( 29141705 )
2018

Variations for Plague

Expression for Plague

Search GEO for disease gene expression data for Plague.

Pathways for Plague

GO Terms for Plague

Cellular components related to Plague according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CCR5 CD83 CD86 PECAM1

Biological processes related to Plague according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to interleukin-1 GO:0070555 9.26 MYD88 SELE
2 leukocyte cell-cell adhesion GO:0007159 9.16 PECAM1 SELE
3 positive regulation of interleukin-8 production GO:0032757 8.96 DDX58 MYD88
4 viral process GO:0016032 8.92 CCR5 CD86 CDC25C DDX58

Molecular functions related to Plague according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 coreceptor activity GO:0015026 8.62 CCR5 CD86

Sources for Plague

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....